Cash to Cures: California's Stem Directors Begin Today's Meeting

Directors of the $3 billion California stem cell agency this morning began a key meeting in Los Angeles as they pursue new directions and more cash to continue their efforts beyond 2017.

The two-day meeting also will see action on about $100 million in awards in the agency's ambitious disease team round, which is aimed at pushing research into clinical trials. Additionally on tap is discussion of the search for a new president.

Bloomberg: California Stem Cell Cash Shrinking, Pressure for Results

The headline this morning on Bloomberg News read “California’s Stem-Cell Quest Races Time as Money Dwindles.”

 The status report on the $3 billion California stem cell agency came as its 29 directors meet in Los Angeles today to consider new directions for the agency – not to mention finding a source to replace the funding which runs out in 2017. (Live coverage of the meeting will begin at 9 a.m. PST on the California Stem Cell Report.)

 The article by Mark Melnicoe is a rare national/international look at the Golden State's unprecedented, nine-year-old effort to turn stem cells into cures, as the agency's motto goes. The California Institute of Regenerative Medicine (CIRM), the formal name for the agency, is largely ignored by the national media. California news outlets also devote few resources to covering agency matters.

Melnicoe's piece covers familiar ground for readers of California Stem Cell Report and others familiar with the agency. But it is a valuable tool for understanding how “outsiders” may view the effort.

Melnicoe wrote,

“California’s government-run stem-cell research agency, on course to spend $3 billion in taxpayer money to find treatments for some of the world’s most intractable diseases, is pushing to accelerate human testing before its financing runs out.”

He continued,

“The largest U.S. funding source for stem-cell research outside the federal government, it’s under pressure to show results to attract new money from pharmaceutical companies, venture capitalists or even more municipal bonds. 

“'We need to figure out how to keep them going,' said Jonathan Thomas, a founding partner of Saybrook Capital LLC in Los Angeles, and chairman of the institute’s board, which meets today. 'We could do public-private partnerships, venture philanthropy, a ballot box.'” 

The Bloomberg article also sounded a cautionary note. It said,

“Brock Reeve, executive director of the Harvard Stem Cell Institute, said a rush could waste money by going too far down paths with false promise. 'There have been a lot of clinical trials in the stem cell field broadly that haven’t panned out,' Reeve said.” 

Specifically mentioned in the Bloomberg piece was the clinical trial by Geron, the first in the nation of an hESC therapy, which was partially financed with a $25 million CIRM loan. The trial was abandoned by Geron, which then sold its stem cell assets to Biotime, an Alameda, Ca., firm, whose top executives come from Geron. Biotime has not resumed the trial.

California Stem Cell Researchers Fight for Shared Labs

Twenty California stem cell scientists are seeking to save the state's heralded, $72 million “shared” stem cell lab program, arguing that it is vital to research and necessary for the continued training of scientists.

The researchers made their appeal in a letter (full text below) expected to be presented tomorrow to the governing board of the $3 billion stem cell agency, which funds the effort. The agency's new Scientific Advisory Board (SAB) has recommended the program be discontinued and more emphasis placed on a handful of clinically oriented projects.

In a very brief recommendation that has been accepted by CIRM staff,  the advisory board said that “the importance of these resources to the mission of CIRM and achieving sustainability of earlier investments is not as compelling (as when the program began).

The SAB continued,

“These resources should operate on a revenue-neutral basis through recharge mechanisms and gain other needed support from the host institutions.” 

The lab program began as a $50.5 million effort in 2007 and was given an additional $21.5 million in 2011 after CIRM staff cited its "exceptional" performance. Former CIRM Chairman Robert Klein praised the effort, citing its ability to leverage funding. He said,

“The $4 million awarded, for example, to Stanford for its shared lab have enabled its scientists to successfully compete for $35 million of grants from numerous sources, with another $15 million in process.”

Responding to the SAB recommendation, supporters of the labs said that without them, “development of protocols for generation of clinically needed cell types will not be possible.” Their letter said the 17 labs have been “vital to current and future CIRM-funded efforts.” There is “no alternative place' for the type of research underway at the labs, said the scientists.

The researchers signing the letter were from institutions throughout the state, including UCSF, Stanford, UC Berkeley, USC, UCLA, Salk, Scripps, Sanford Burnham, UC Irvine and UC Santa Barbara.

The letter, which was made available to the California Stem Cell Report,  said,

“In the worst case scenario, the loss of indirect cost support to the institutions will mean that the core lab space will be reallocated (a certainty for many independent research institutes), effectively dismantling the Shared Laboratories and putting CIRM equipment into storage. Shared Laboratory personnel provide support not only for the millions of dollars of CIRM purchased equipment, but often also the additional equipment that has been funded by other sources as a result of the CIRM infrastructure investment but often also the additional equipment that has been funded by other sources.... 

“Even in the best cases, there will be no means to support the staff and maintain the equipment. Some institutions may be able to provide space without indirect costs, but will not fund personnel and equipment maintenance. Thus, the original CIRM investment in infrastructure will be lost, and CIRM’s highly successful training programs for new workers (CIRM Bridges and Training Grants), will be left without homes.”

Here is the full text of the letter and a summary of survey of activity at the shared labs.

California Scientists Back Endangered Stem Cell Lab Program

Survey on California's Shared Stem Cell Lab Program posted by DavidJensen

Live Coverage of Tomorrow's Hefty Meeting of the California Stem Cell Agency

The California Stem Cell Report will provide gavel-to-gavel coverage of the meeting tomorrow and Thursday of the governing board of the California stem cell agency, which is scheduled to give away roughly $100 million and at least initially lay out its future direction.

The Los Angeles meeting begins at 9 a.m. PST tomorrow and is scheduled to end at 4:30 p.m. Stories will be filed as warranted.

For those wanting to participate in the meeting, the location in Los Angeles can be found on the agenda. Remote teleconference locations for participation are located in Sacramento (tomorrow only), La Jolla, Pleasanton, Costa Mesa and Davis. Addresses are on the agenda.

Also on the agenda are instructions for listening via an audiocast (listen only) and a Webinar Web site that provides access to Power Point presentations used by staff.

The agenda is robust, to use one of the agency's favorite words, and is loaded with data and information on virtually all of the items. However, much of the information is raw with little analysis concerning its significance.

The California Stem Cell Report will base its coverage on the Internet audiocast from its post aboard a sailboat in Huatulco, Mexico.

The Elusive Stem Cell and the Power of Hope

It was, you might say, the best of times and the worst of times last week for the stem cell community, particularly in California. At least based on a spate of headlines and news stories.

Largely ebullient rhetoric rolled out of San Diego, only to be tempered or contradicted elsewhere. The World Stem Cell Summit was underway in Southern California, generating a small wave of coverage.

On Tuesday, Bradley Fikes of the San Diego UT reported,

“Stem cell research has already yielded historic breakthroughs against incurable diseases, a panel of top stem cell researchers said at a public forum Tuesday evening. And that's just the start....”

On Wednesday, the $3 billion California stem cell agency carried on with the theme and blogged about “breakthroughs.”

On Thursday, GEN News quoted Bernard Siegel, the major domo of the summit, as saying,

 "The field is a true scientific revolution and reflects the transformative power of hope...."

But then there was this midweek story, also by Fikes,

“Stem cell research faces a budget crunch -- The cash-strapped federal government’s ability to fund stem cell research has become severely limited....”

On Saturday, Bloomberg headlined a discouraging story about research based in Boston,

“HIV Returns in Two Men Thought Cured After Stem Cell Transplant."

And earlier in the week, a consultant to the $3 billion California stem cell agency made it clear that after 2017, it will no longer be handing out $300 million a year in research grants. His report also noted that it would take 10 years or so for stem cell research to emerge from early clinical trials to become real, commercial therapies.

The diverging stories and comments reflect the ebb and flow of a young technology. They also reflect the inveterate optimism of many researchers and patient advocates, who publicly see few barriers to stem cell therapies. Catriona Jamieson, a scientist at UC San Diego who appears to be enjoying remarkable success in her work, last week commented,

"The biggest barrier is nihilism."

Cash is short, however, not only in the federal government and at the California agency, but also in the private sector, which has basically stiff-armed stem cell research for the last several years or longer.

Despite some recent, promising signs of interest from some companies, Siegel's comment may be the most on the money about the current state of affairs: The stem cell field continues to reflect the “transformative power of hope.” And widely available, safe, effective and reasonably priced stem cell therapies remain elusive.

$98 Million for Stem Cell Therapies for Cancer, Arthritis and More

Directors of the California stem cell agency this week are expected to approve nearly $98 million in awards for early stage clinical trials for treatments of diseases ranging from sickle cell anemia to cancer.

The awards will involve the $3 billion agency's signature disease team program, which is aimed at pushing stem cell research into the marketplace.

In addition to sickle cell anemia and cancer(see here, here and here), the applications involve therapies for macular degeneration, arthritis and severe airway obstruction. Names of the applicants were withheld by the agency. The identities of successful applicants will be released following board action. Names of the rejected applicants, however, are not released by the agency. The number of business applications was also not immediately released.

The goal of the latest round in the disease team program is completion of an early phase clinical trial during the award period, which can be up to four years. Amounts of the proposed awards range from $20 million to $4.4 million. CIRM originally budgeted $100 million for this round.

Four applications won outright approval from the agency's grant reviewers. CIRM staff recommended that three out of four “tier two” grants be approved. The scientific scores of all seven of those applications range from 79 to 67 on a scale of 100.

Some of the five rejected applicants and sympathetic patient advocates may well appear at the board meeting in Los Angeles on Wednesday and Thursday to lobby for their proposals. The CIRM board can fund any of the applications, regardless of their scientific scores.

Here are links to the ample information provided by CIRM staff on the grant applications: summaries of the grant reviews, staff justification for funding tier two applications, Power Point presentations to be made to directors on the applications, including the range of scores on individual applications. However, the range of scores on the rejected applications was not provided.

The Californa Stem Cell Agency: A Blueprint for Living Without $300 Million a Year

The likely future of the $3 billion California stem cell agency was unveiled this week, and it envisions an enterprise no longer tied to state funding and much more closely linked with industry as a collaborator and “bundler” of resources.

Gone would be the $300 million a year in cash that the state borrows so that agency can award grants to academics and occasionally to business. Likely to be missing are faculty recruitment awards, non- business training programs and perhaps most of the agency's basic research effort.

Instead, the California Institute for Regenerative Medicine(CIRM), as the agency is formally known, would build a relatively small number public-private partnerships to back projects close to turning out commercial therapies. It would ally itself with the Alliance for Regenerative Medicine, a national lobbying and industry group in Washington, D.C. And the agency's funds would come possibly from foundations, philanthropists, investors, biopharma, the health insurance industry and federal agencies such as the NIH and Medicare.

That is part of the scenario painted in a $150,000, 69-page report by consultant James Gollub of Tiburon, Ca. CIRM earlier this year commissioned the report because the agency will run out of state funds for new grants in 2017.

The governing board of the stem cell agency will hear a report on the Gollub's recommendations at its Dec. 11 and Dec. 12 meeting in Los Angeles. The report will come as part of consideration of proposals by the agency's new Scientific Advisory Board that the agency should sharpen its focus on six to eight projects to push them closer to bearing commercial fruit. The proposed “strategic roadmap” also comes as the agency is looking for a new president to replace Alan Trounson, who is leaving to rejoin his family in Australia.

Trounson has prepared an outline of a plan on how to start implementing the proposals.

Gollub made three major recommendations, one of which would require a $50 million investment from CIRM with another $50 million to $100 million coming from other sources, including wealthy individuals such as businessman Denny Sanford who recently gave UC San Diego $100 million for stem cell research.

The report said additional costs, including those for outside consultants, could be absorbed by CIRM or funded through awards on a charge-back basis. In others words, a grant would include funds that a researcher would have to pay to the agency for its “internal program management services.” CIRM is limited by law to an operating budget that can total only 6 percent of its $3 billion, which keeps its overhead quite lean.

Gollub noted that that CIRM has already moved partially into the areas of his three proposals, all of which would begin in the next year or so. They are:

• Create public-private partnerships to move projects into early clinical trials, focusing on specific disease areas. Co-funders providing at least $50 million would screen and select the projects from those presented by CIRM. This could be scaled up from a pilot project next year and possibly involve creation of a nonprofit group by CIRM.
• Create a “regenerative medicine accelerator” to provide “commercial readiness services” to each(Gollub's italics) grant recipient whether academic or business. The accelerator effort would be linked to agency's proposed $70 million Alpha Clinic plan. The accelerator also would assure that the “clinical trials structure meets pharmaceutical industry expectations.”
• Create a pre-competitive regenerative medicine R&D program that would organize collaborative efforts to break through barriers to development of therapies. This would involve production but also what the biotech industry calls “reimbursement,” which is a catch word for making a profit from development of a therapy. One of the issues in the industry is the expense of some medical treatments, and stem cell therapies are expected to be very high. The idea is to work with the insurance industry and the federal government to be sure the appropriate cost is supported by Medicare and insurance programs. Partnering with the Alliance for Regenerative Medicine would enter into this effort, which would be ultimately funded by both CIRM, the new non-profit and other partners.

The general direction of the recommendations is to “de-risk” stem cell therapy development and provide a focal point for overcoming many of the regulatory and manufacturing obstacles facing a new medical technology.

The report said CIRM has as a “strong innovation feedstock” of more than 90 projects that are close to moving into clinical trials. Some of those projects are likely to appeal to Big Pharma, which has been increasingly looking outside of its own companies for R&D.

For donors willing to pay for the privilege, Gollub's “strategic roadmap” recommended that CIRM create a group that would have “'a seat at the table' to see early stage  research, discoveries and clinical performance.”

The report said the CIRM's new world would require a “robust, dedicated fundraising group” within the agency, which now has minimal capacity in that area. However, the study envisions members of the governing board, many of whom are top notch fundraisers, as making a major effort to raise cash.

Scaling up the initial public-private partnerships, accelerators, etc., would also require additional staff. Gollub's report did not present costs beyond the initial pilot project stage.

California Stem Cell Report Taking Some Time Off

The California Stem Cell Report is going dark for a number of days while yours truly makes an ocean passage from Chiapas to Zihuatanejo.

As some of you know, this report is published from a sailboat called Hopalong on which this writer lives fulltime south of the border with his spouse. And Hopalong does move about from time to time.

We may have Internet access along the way to monitor the affairs of the California stem cell agency but cannot count on it. We should be back to the grindstone in about two weeks.

Searching for CIRM's Financial Future, Plus a $100 Million California Stem Cell Round

The California stem cell agency next week is expected to give away as much as $100 million as it pushes aggressively to generate therapies that will benefit the Golden State as well as the world.

At the same time, the agency will decide whether it will focus more intensely on a handful of projects as it tries to come up with a plan to finance its future. The $3 billion agency is currently funded by money that the state borrows, but cash for new grants will run out in 2017.

The agency is looking for a way to continue operations through some sort of public-private partnership. A consultant's report was due on that subject on Nov. 30. At its meeting Dec. 11 and Dec. 12 in Los Angeles, the board is scheduled to spend one hour hearing a presentation on the report at the end of a lengthy examination of recommendations from the agency's new Scientific Advisory Board(SAB), the panel that proposed that CIRM sharpen its focus. The California Stem Cell Report has asked for a copy of the document, which is a public record.

The SAB report plays into the agency's need to come up with results that will stimulate both private and public interest in supporting the agency's future operations. So far, CIRM has lacked the research results that resonate widely with the public.
 
The agency has prepared a tightly organized schedule for examining the SAB proposals, which could mean that the agency's shared labs, bridges and training grants programs would be phased out. However, CIRM staff is only recommending an end to the shared labs program.

The staff has proposed creation of an “accelerated development pathway” for six to eight projects, as recommended by the SAB. The staff document did not describe what that would entail or how much it would cost.

Also on the staff list is a proposal to advance the most promising early translational research programs and a $10 million proposal by CIRM President Alan Trounson to participate in a global effort “to create (a) Haplotype Bank and GMP library.” No further details on that plan were available at the time of this writing.

For the stem cell community, the immediate big news next week will be board action on applications in its signature disease team program. This is the third round, and awards could run as high as $20 million each for a total of $100 million. The round also involves possible collaborators in England, Spain and China, a country that has been pushing hard on stem cell research. No state funds will be used overseas.

According to the RFA, the purpose of the disease team effort is “to advance early clinical development of novel therapies derived from or targeting stem cells, potentially offering unique benefit with well-considered risk to persons with disease or serious injury.”

The summaries of the grant review findings have not yet been posted on the CIRM Web site, but are likely to come later this week. The CIRM governing board almost never overturns a positive recommendation from its reviewers. Sometimes it will approve an application rejected by reviewers. However, directors are feeling squeezed financially and may not be as open to elevating rejected applications as they have been in the past. Look for rejected applicants to personally petition the board for approval along with affected patient advocates.

Also on the agenda is the topic of the search for a new president for the agency to replace Trounson, who is resigning to return to Australia and his family. An item was posted on that yesterday.

Next week's meetings are open to the public in Los Angeles and at teleconference locations in La Jolla and Pleasanton. Addresses can be found on the agenda. The board also usually provides an Internet audiocast and a Webinar link to PowerPoint presentations used at the meeting. Directions for using those tools are likely to be posted on the CIRM Web site later this week.

California Stem Cell CEO Search: Non-Scientist Candidates Quite Welcome

The $3 billion California stem cell agency could well have a non-scientist as its new president as it pushes to develop commercial products and develop future funding sources for the nine-year-old research enterprise.

Directors of the agency meet next week to settle on the criteria for the new CEO, who directors would like to see in place as soon as possible. Specifically missing from the board's latest wish list is a requirement that the individual be a scientist or researcher. Instead, the criteria say candidates should have “experience with and personal commitment to medical and scientific research including familiarity with stem cell research.”

In terms of academic credentials, the proposed criteria specify either or both an M.D. or Ph.D. degree or “equivalent industry experience or similar body of knowledge developed in professional roles.”

That sort of broad description could mean several things. One is that the board already has a candidate in mind and directors don't want to hampered by perceptions that only a scientist can run CIRM, as the agency is known. The description also significantly widens the field of possible candidates, virtually inviting non-scientists to apply for the position, which carries a salary of up to $548,788 annually.

The criteria, however, make it clear that candidates should be heavyweights in development of scientific products. The agency wants tested leaders of scientific organizations, experience with R&D, including the regulatory process for development of new treatments, and persons who have no problem shutting down projects that aren't going anywhere.

The latest job description for the person to replace CIRM President Alan Trounson, an internationally known scientist, came together after an earlier meeting of the board's Presidential Search Subcommittee, which will review and perhaps modify it at a public meeting Dec. 10 in Los Angeles. Then the full board will act on it during its two-day meeting Dec. 11-12, also in Los Angeles.

Teleconference locations for both public meetings can be found on their agendas, which are here and here.

December Decision on Sharper Focus at California Stem Cell Agency?

A key panel at the $3 billion California stem cell agency has set the stage for action next month on recommendations that it move “at speed” to sharpen its focus to on six to eight projects likely to come closer to turning research into cures.

The governing board's Science Subcommittee met last Friday to discuss the recommendations from the agency's new Scientific Advisory Board. The proposals were first heard by CIRM directors in early October. No action has been taken so far but the advisory board's report comes up again Dec. 11.

Responding to an inquiry, Kevin McCormack, spokesman for the agency, today said last week's meeting gave the subcommittee and staff a chance to discuss the recommendations and possible action. Some of the recommendations could mean a lessening of financial support for some CIRM programs.

The agency has awarded $1.9 billion and has about $600 million in unallocated funds. It will run out of cash for new awards in 2017 and is working on a plan for future financial support. A consultant is expected to suggest a plan to the board also at its December meeting.

The full text of the recommendations and the staff's response can be found here.

New Public Finance Aide Appointed at California Stem Cell Agency

The California stem cell agency has named a veteran staffer to fill a key slot in developing a plan for its financial future beyond 2017.

Amy Lewis
CIRM photo

She is Amy Lewis, who has been with the agency since the very beginning. Indeed, her work in connection with CIRM, as the agency is known, dates back to the ballot initiative campaign that created CIRM in 2004.

In response to an inquiry, Kevin McCormack, chief spokesman for the agency, said Lewis previously served as grants management officer after working as deputy chief of staff to then CIRM Chairman Bob Klein. Her new title is deputy to the chair for public finance and governance.

During the campaign for Prop. 71, she was the “lead development staffer” in Northern California, McCormack said. She has an MBA from the University of San Francisco with an emphasis in finance.

Lewis will be a key aide to CIRM Chairman Jonathan Thomas, who is working on a plan to finance the agency after its money for new grants runs out in 2017. The position that she fills was reconfigured after the departure of Lynn Harwell to spell out that it would involve “meeting the financing and sustainability goals” of the agency.

Parsimony and Stem Cells: California's Changing Cash Outlook

Last week it was California Gov. Jerry Brown's financial “reality sandwich.” This week it is Mac Taylor's prodigious fiscal feast.

Both men are key players in California's economic scenario and quite possibly the future of the California stem cell agency.

Taylor does not have the household name that the governor does. But he is the state's legislative analyst, the bipartisan and widely respected expert and adviser to the California Legislature on state spending and income.

Taylor's message this week came in sharp contrast to the picture of parsimony drawn last week by Jerry Brown when he warned UC Regents to lower their expectations about their request for $120 million more than he thinks they should have. The governor said there are many competing interests that have legitimate claims to state funding in addition to the University of California. It was language that could apply to the stem cell agency, which will run out of cash for new grants in 2017 and is hoping for more public support.

Brown's remarks covered really only the next 18 months. Taylor on the other hand covered that period and beyond, into 2020.

Gone are $100 billion in cumulative state deficits over the last four years. Instead, by 2018, the state could be running annual budget surpluses of $10 billion, according to an article by James Nash on Bloomberg News concerning the legislative analyst's report.

Taylor's analysis is not necessarily directly at odds with Brown's views. They were both discussing the budget but in different ways. Nevertheless, it comes as good news for the agency. More state cash means a greater likelihood that large amounts can be funneled into stem cell coffers.

Taylor's forecast was also widely celebrated by the many other petitioners who have seen their favorite programs suffer during the Great Recession.

Jerry Brown, however, was not sanguine about California's spending. According to David Siders of The Sacramento Bee, the governor is not budging from frugality and plans “to say no when necessary.” Siders quoted him as saying,

“We have deferred maintenance on our roads, that is serious, we have unfunded and growing liabilities in our pension and retiree health – state, university and local level. That’s real.”

Timing is everything for the stem cell agency. If it can catch the state on an upward financial bounce and show results that resonate with policy makers, good things could happen. But Taylor also noted that even a modest economic downturn could send the state once again into deficit spending. And, ironically, rising costs for health care, an issue of considerable concern to the stem cell agency, could be one of the competing interests that could squeeze out spending for stem cell research.

California Stem Cell CEO Search: More Names Surfacing­

While the $3 billion California stem cell agency awaits help from an executive search firm, more names are being mentioned as possibilities to become the new president of the organization.

Keep in mind that these are names that the public is bandying about, not any sort of official CIRM directors' list, which may not exist at this point.

UC Davis researcher Paul Knoepfler triggered the discussion of possibilities this week when he posted a list of a dozen names that people in the field have suggested might be considered. As a result, Knoepfler ­received suggestions from his readers of additional possibilities.

They include Ellen Feigal, the No. 2 person at the agency, and Arlene Chiu of Cedars-Sinai, who was chief scientific officer at the agency until she left in 2007.

Knoepfler also emphasized that the dozen names he listed do not constitute any sort of CIRM list. If some readers may think he is floating trial balloons for the agency, that does not appear to be the case.

Knoepfler's entry into this obviously speculative arena, however, is worthy. Bringing specific names into the discussion could well help sharpen both the focus in the search and the understanding of the type of trade-offs that are likely to be necessary. It also may stimulate comments from people in the stem cell field about what is needed in a new president. Those comments can either be forwarded to the agency or laid out in public commentary either here or on Knoepfler's blog.

As for the executive search firm, the agency hopes to have a contract signed by Dec. 16. But it is certain that some agency board members have already put out tentative feelers to suitable persons.

On Oct. 16, CIRM President Alan Trounson announced his plans to depart and no doubt is increasingly focused on returning to Australia and his family, especially as the holiday season approaches.

California's Stem Cell CEO Search: The 'Not-So-Knoepfler' Dozen

A few comments trickled in today concerning yesterday's item on the 12 possibilities who could be considered as candidates to become the new president of the $3 billion California stem cell agency.

The dozen individuals were listed by UC Davis researcher Paul Knoepfler in an item on his blog. The California Stem Cell Report piggybacked on that piece, adding some additional information in an item that included the expression “the Knoepfler dozen.”

This morning Knoepfler wanted to clarify that he was not necessarily personally recommending any of them.

He said,

“To be clear, these are not the 'Knoepfler Dozen.'. These are not my picks for candidates. In fact I took myself out of the equation in terms of intentionally not including my own opinions so these 12 represent specifically the ideas of others for CIRM presidential candidates, not my own. I think some of these are great candidates, but I have some others too in mind. Maybe I should do another post on that.”

We also received an email from a Minnesota researcher who said, “Do you really think this is the list?  Hmmm.”

No, I do not believe this is CIRM's list. But some persons mentioned might have been discussed by some CIRM directors informally as possible candidates. As I noted, at least one person on the list has been considered in the past.

Finally, one of the persons on the list, who must remain nameless, emailed this question in connection with a comment in last night's item that great researchers are often terrible managers: “I'm a terrific manager. Does that make me a bad scientist??”  

The Knoepfler Dozen: Kicking Around Names for Stem Cell Agency Presidency

A UC Davis stem cell researcher today came up with a list of 12 persons who have the “stem cell chops” to become the new president of the $3 billion California stem cell agency.

They include a few folks from the NIH, two women and one of the earliest pioneers in the nation in stem cell research.

Writing on his blog, scientist Paul Knoepfler pulled together the names based on “behind-the-scenes” discussions with “some folks in the know.” It is much too early in the process to identify genuine candidates. Nonetheless, they are possibilities, however remote, and represent the type of persons that Knoepfler and his colleagues are talking about.

A couple of caveats when evaluating these names and whether they would even consider leaving their current, very nice positions. One is that they would have to give up their labs. Outgoing CIRM President Alan Trounson has lamented more than once about how he had to do that. Also, questions arise about whether a person considering the post would want to leave his or her current employment for a job that could basically vanish in less than three years.

The agency will run out of money for new grants in 2017. Unless it finds additional funding, the last few years of operations beyond 2017 will involve simply administering the last grants. Even if it does raise more cash, it is exceedingly unlikely that the agency will be able to continue hand out $300 million a year.

That said, here are Knoepfler's dozen. First, the women: Jeanne Loring of Scripps and Story Landis of the NIH. The stem cell pioneer is Michael West, CEO of Biotime, who founded Geron back in 1990.

The others are Jim Battey, who was previously a late stage candidate for the job, and Mahendra Rao, both of the NIH; Rusty Gage of Salk, Larry Goldstein of UC San Diego, Arnold Kriegstein of UC San Francisco, Tom Okarma, former CEO of Geron and now head of Asterias Biotherapeutics, which now owns Geron's stem cell assets, Brock Reeve of Harvard, Clive Svendsen of Cedars-Sinai and Keith Yamamoto of UC San Francisco.

Notably missing from the list are possibilities from Stanford, UCLA and USC.

A note re Goldstein of UC San Diego, he was recently named to head the $100 million Sanford stem cell operation, which makes it unlikely he would move to the stem cell agency.

CIRM's job description also currently carefully omits a requirement that the new president be a scientist, only that the person have scientific credibility.

One scientist knowledgeable about CIRM's operation recently told the California Stem Cell Report that great scientists often make terrible managers, a sentiment that may come into play during the selection process.

California's Stem Cell CEO Search: Directors Emphasize Speed, Job Description Changes Underway

Directors of the California stem cell agency are rejiggering the job description for the new president of the $3 billion research enterprise, including possibly language that says that the person does not necessarily have to be a scientist.

The directors' Presidential Search Subcommittee met last Friday to take its first crack at the task of hiring someone to replace Alan Trounson, who is returning to his home in Australia to rejoin his wife and family. The agency has also posted a request for bids from executive search firms to assist in the task.

The California Stem Cell Report queried the agency about the outcome of Friday's meeting, some of which occurred behind closed doors. Kevin McCormack, a spokesman for the agency, said via email,

“There are a number of revisions being made to the (job) description to update it and that will be circulated to the subcommittee when they are done.”

We asked specifically about the language in the description that said the new CEO had to have “scientific credibility” but omitted a requirement that the person be a scientist. McCormack replied,

“There were so many suggestions on what to include in the criteria that I would be hesitant to definitively say what's in and what isn't. Hopefully we'll have the new criteria shortly.

“There was one very clear message that we want to expedite this to get a new president as quickly as possible.”

McCormack said the subcommittee will meet again before the full board meeting that begins Dec. 10.

Sharing Jerry Brown's 'Reality Sandwich:' The California Stem Cell Angle

California Gov. Jerry Brown yesterday served up a “reality sandwich” that may not augur well for the financial future of the $3 billion California stem cell agency.

It was a “lower-your-expectations” message that harkened back to Brown's first term in office when he surprised many in the state with his frugal ways.

Brown delivered the news to the University of California regents, one of whom is also Sherry Lansing, a longtime and influential member of the 29-member governing board of the stem cell agency.

Brown told the regents that he plans to budget the university for a $146 million increase (5 percent) in state funds during the upcoming fiscal year. The regents want an additional $120 million. Brown said that was not going to happen.

David Siders of The Sacramento Bee reported that Brown, who once studied for the Catholic priesthood, told regents that they may think that his "Jesuitical harshness is not nice.” But he said that there are many competing interests within the state and "that's kind of the reality sandwich we have to chew on."

UC Regent Lansing said that she is not ready to give up on more cash for UC and that she believed in UC's “power of advocacy,” according to Katy Murphy, writing in the San Jose Mercury News. Last summer, at the stem cell agency's governing board meeting in July, Lansing also stressed the need for “renewal of the (state) bond money” that finances the operations of the agency, which is known as CIRM.

The stem cell enterprise faces a more serious fate than the University of California. The agency will run out of money for new awards in 2017. It is looking at some sort of public-private partnership to continue its efforts. Its initial assumptions include as much as $200 million in public support.

The state's economic situation could improve within two years. However, the pressing demands of a host of high priority needs in California will increase as well. Stem cell research will face tough competition against the many compelling state problems that have been given short shrift during the past five years or more.

That's all part of the “reality sandwich” for CIRM to sample in December when its directors will be briefed on a new plan for financing the agency's future.

South Dakota Catches Up on $100 Million Sanford Stem Cell Donation

For Denny Sanford, it was close to one of those moments when, as Samuel Johnson once said, your mind is concentrated “wonderfully.” Or not-­so-wonderfully.

For Sanford it came Oct. 19, just 15 days before he announced he was giving $100 million to UC San Diego for stem cell research.

“I was within minutes or hours of death," he told reporter Jon Walker of the Argus Leader newspaper in South Dakota earlier this week. Sanford, 77, had suffered a near fatal blood clot in his lungs at 2:30 in the morning while on a pheasant hunting trip near Gregory, S.D.

“I couldn’t walk or breathe. It’s pretty scary when you can’t walk eight or 10 feet.”

Sanford called his physician at Sanford Health in Sioux Falls, S.D., who launched the facility's emergency plane. The billionaire was treated successfully and now reports he is back in the San Diego and in good condition.

Sanford is famous in both San Diego and South Dakota for giving away more than $1 billion. He still has about $1 billion but says he plans to give it all away and die broke. His largest contribution, $400 million, has gone to Sanford Health.

Sanford has spent years in South Dakota and is often described as a South Dakota resident. However, the Argus Leader says he is a former Sioux Falls businessman who has homes in South Dakota, Arizona and California.

Walker's newspaper is part of the Gannett chain that also operates USA Today, which yesterday picked up the reporter's two stories , one on the California stem cell donation and one on Sanford's lung blockage. The two articles were combined and rewritten by USA Today to focus on the $100 million stem cell donation. Walker's byline was put on the story in keeping with common newspaper practices. It was a score for Walker to have a byline on a national story in a national publication with 2.88 million circulation.

(Samuel Johnson had a number of things to say about close encounters with mortality. Here is a link to one.)

Scientific Advisors to Stem Cell Agency: Time to Move 'At Speed'

John Bell, chair of CIRM SAB
Academy of Medical Sciences photo

The $3 billion California stem cell agency is preparing to take a close look at recommendations from key advisors that it should focus more sharply on a handful projects in order to transform research rapidly into commercial therapies.

The governing board's Science Subcommittee on Nov. 22 will examine the proposals by its new Scientific Advisory Board(SAB), created last summer as the result of a $700,000 Institute of Medicine study. Among other things, the advisory board said CIRM directors should zero in on six to eight projects that would lead to early stage clinical trials.

The recommendations come as the agency, known as CIRM, is wrestling with its own mortality. Cash for new awards will run out in 2017. The directors next month will hear a consultant's report on a plan for financing the agency's future. It is expected to involve some sort of public-private funding, which will only be forthcoming if the agency demonstrates research results that resonate with possible funding sources.

At last month's governing board meeting, CIRM director Sherry Lansing, a former Hollywood film studio chief, former chair of the UC regents and a prodigious fundraiser, sounded an urgent note.

She said that the agency is “trying desperately to get a win.” She raised the possibility of putting out a “do-you-need-help” RFA which would target applicants that have well-developed projects that could be moved ahead rapidly with some cash.

The Oct. 9 board meeting was the first time that Lansing and the other 28 CIRM directors had seen the recommendations, which were prepared outside of public view. They were only received by the agency staff two days before the board meeting.

The agency has yet to post on the Internet the full SAB document. However, the California Stem Cell Report asked for a copy, and the complete text can be found at end of this item.

 The report said,

“(F)or stem cell research to continue to advance at its current pace in California, future potential investors and supporters of stem cell research must perceive a tangible benefit to human health, and this can only happen through a clear success at the stage of clinical proof of concept. It is important that this occurs during the currently projected lifespan of CIRM, so that deserving projects and resources are positioned in the strongest way possible to attract future investments after expiration of the current CIRM funds.”

The agency's scientific advisors, only one of whom is from California, said the agency has a “strong chance of success” in securing additional funding if it moves “at speed.”

The panel, chaired by Sir John Bell of Oxford University in the United Kingdom, said it was “optimistic” that “a clinical proof of concept can be achieved in one or more settings with CIRM projects within the next three years.”

The report contained some comments that indicate that the advisors are not fully aware of all the circumstances surrounding CIRM. The panel prepared its report after being briefed by CIRM staff and four academic recipients who had received CIRM awards. No representatives from industry were heard. The advisors' report said,

“The SAB had a very positive view of the interactions between CIRM and the commercial sector.”

Many in the biotech community, however, have been less than pleased with CIRM, to point of holding a private dinner to air their grievances with then CIRM Chairman Robert Klein, filing multiple appeals of grant reviewer decisions and testifying before the Institute of Medicine. Only a tiny percentage of the $1.9 billion in CIRM awards has gone to business.

The agency, however, is working diligently to improve its industry relations, which are critical to turning research into something that can actually be used in the marketplace.

The advisors, handpicked by departing CIRM President Alan Trounson, praised CIRM's achievements so far as “considerable” and “transformative.” But it noted that the agency lagged behind other funding bodies in terms of “attention and attribution.”

The panel said,

“CIRM has been catalytic in generating many of the scientific advances in this field, but its brand recognition internationally and even nationally is limited and this should be corrected.”

The agency has suffered in the past from PR missteps but has been moving with some success in the past year to gain more favorable attention. However, it remains a relatively young organization. It receives almost no coverage in the mainstream media and very little more in the scientific media. Breaking through the media clutter is difficult, especially given that CIRM has not been part of major stem cell developments that naturally generate front page attention.

The SAB recommendations have been largely endorsed by the agency's staff. Following the Nov. 22 meeting on the proposals, they will go to the full governing board at its December meeting for action. The public can attend the meeting Nov. 22 in San Francisco and a teleconference location in Duarte at the City of Hope. Advance comments can be filed with CIRM via email at info@cirm.ca.gov.

  Scientific Advisory Report California Stem Cell Agency October 2013